AstraZeneca beats expectations in Q2, while GSK struggles du...

AstraZeneca has beaten analysts’ expectations in its second quarter results, outshining its UK counterpart GlaxoSmithKline, which has been hit by disruption caused by the COVID-19 pandemic.

Trump reiterates hydroxychloroquine defense after son is ban...

Donald Trump has launched another defence of hydroxychloroquine as a treatment for COVID-19 which goes against prevailing medical advice.

Novartis, company culture and COVID-19: the pharmaphorum pod...

Novartis’ Steven Baert joined the pharmaphorum podcast for episode 22 to discuss how COVID-19 will change the face of company culture, now and in the future.

UK places order for 60m doses of Sanofi/GSK’s COVID-19 vacci...

The UK government has signed its fourth coronavirus vaccine deal, snapping up 60 million doses of an experimental shot being developed by Sanofi and GlaxoSmithKline.

Setback in COVID-19 effort as Roche's Actemra fails in key t...

Roche’s anti-inflammatory drug Actemra has failed in a phase 3 clinical trial that was testing to see if it improved the condition of patients with COVID-19 associated pneumonia.

Understanding COVID-19 and varying responses across the glob...